StoxCuris Lifesciences Limited
NSE: CURIS · Unclassified
Ask the data
Instant answers about Curis Lifesciences Limited — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY26 | |
|---|---|
| Revenue | 60.6 |
| EBITDA | 11.1 |
| Operating margin | 18.4% |
| Interest | 1.1 |
| Depreciation | 0.7 |
| Profit before tax | 9.6 |
| Tax | 2.6 |
| Net profit | 6.9 |
| EPS ₹ | 10.26 |
| Operating cash flow | -16.4 |
| Capex | 1.8 |
| Dividend paid | 0.0 |
| Total assets | 81.5 |
| Equity | 47.4 |
Half-yearly performance
last 2 half years · ₹ crore| H1 FY26 | H2 FY26 | |
|---|---|---|
| Revenue | 27.9 | 32.7 |
| Operating profit | 6.0 | 5.1 |
| Operating margin | 21.5% | 15.7% |
| Other income | 0.0 | 0.3 |
| Interest | 0.4 | 0.7 |
| Depreciation | 0.3 | 0.3 |
| Profit before tax | 5.2 | 4.3 |
| Tax | 1.0 | 1.6 |
| Net profit | 4.2 | 2.7 |
| EPS ₹ | 7.10 | 4.01 |
Returns & margins
trailing-twelve-month, per half year| H2 FY26 | |
|---|---|
| ROE | 14.6% |
| ROCE | 15.5% |
| Net margin | 11.4% |
| EBITDA margin | 18.4% |
| Debt / equity | 0.46 |
| Interest coverage | 9.39 |
| Asset turnover | 0.74 |
Balance sheet
equity vs borrowings over time · ₹ crore| SEP '25 | MAR '26 | |
|---|---|---|
| Share capital | 5.9 | 8.1 |
| Other equity / reserves | 14.5 | 39.3 |
| Total equity | 20.4 | 47.4 |
| Borrowings | 14.8 | 21.6 |
| Current liabilities | 21.9 | 27.4 |
| Non-current liabilities | 7.0 | 6.8 |
| Total assets | 49.4 | 81.5 |
| Property, plant & equipment | 10.8 | 10.8 |
| Capital work-in-progress | 0.0 | 1.3 |
| Investments | 0.0 | 0.0 |
| Inventories | 24.6 | 34.1 |
| Receivables | 9.4 | 11.2 |
| Cash & equivalents | 0.0 | 3.2 |
Cash flow
annual · ₹ crore · line = free cash flow| FY26 | |
|---|---|
| Cash from operations | -16.4 |
| Cash from investing | -1.6 |
| Cash from financing | 20.9 |
| Capex | 1.8 |
| Free cash flow | -18.2 |
| Dividends paid | 0.0 |
Where the assets sit
Mar '26 · ₹ crorePeer comparison
largest in Unclassified · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Avantel Limited | 36,86,04,549 | 138.69 | — | 1059360.68 | 0.0% |
| Ducol Organics And Colours Limited | 19,55,275 | 120.00 | — | 20089.13 | 0.0% |
| Jio Platforms Limited | 12,57,181 | 1,406.40 | — | 3.57 | — |
| SBI Funds Management Limited | 1,01,750 | 499.55 | — | — | — |
| Tamilnadu Telecommunication Limited | 91,314 | 9.93 | — | — | — |
| Manipal Health Enterprises Limited | 76,294 | 646.70 | — | — | — |
| INDO-MIM Limited | 59,042 | 1,219.50 | — | — | — |
| AvenuesAI Limited | 45,138 | 129.25 | 153.6 | 9.51 | 6.2% |
| Dhoot Transmission Limited | 32,761 | 1,601.60 | — | 8.11 | — |
| 3M India Limited | 31,071 | 27,570.00 | 53.8 | 17.57 | 32.7% |
| Curis Lifesciences Limited | 143 | 177.10 | 20.7 | 3.02 | 14.6% |
StoxGud checklist: Neutral setup · 5/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
FAQs
What is the share price of Curis Lifesciences Limited?
Curis Lifesciences Limited (CURIS) closed at ₹177.10 on NSE on 06 Nov 2026.
What is the market cap of Curis Lifesciences Limited?
₹143 crore at the latest close.
What is the P/E ratio of Curis Lifesciences Limited?
20.7, on trailing-twelve-month earnings from its filings.
How fast is Curis Lifesciences Limited growing?
Not enough filed history yet to measure Curis Lifesciences Limited's growth.
How profitable is Curis Lifesciences Limited?
On a trailing-twelve-month basis return on equity is 14.6%, return on capital employed 15.5%, operating margin 18.4%, net margin 11.4%.
How much debt does Curis Lifesciences Limited have?
Curis Lifesciences Limited is lightly geared: debt to equity is 0.46 with borrowings of ₹22 cr against cash of ₹3 cr (balance sheet of 2026-03-31). Operating profit covers interest 9.4 times.
Financials parsed from Curis Lifesciences Limited's own XBRL filings to NSE (standalone), ₹ crore unless marked. Half-yearly from H1 FY26, annual from FY26, balance sheet from Sep '25. * = derived (full year minus the other half). This company is on NSE's SME platform and reports results half-yearly. Information only, not investment advice.